See source for full article.
Since stepping down from his post at the Food and Drug Administration last year, Anand Shah has gone from toiling on the country’s Covid-19 response to updating his LinkedIn with a flurry of new advisory roles at promising startups.
Scott Gottlieb: How to stop the shift of drug discovery from the U.S. to China
Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why…
Thought Leader: Scott Gottlieb
Peter Zeihan and The Fire Hose of Chaos: Port Fees
Peter Zeihan: Today we’re discussing the Trump administration’s 96th tariff policy which imposes port fees on Chinese ships. Chinese ships that enter a US port…
Erika Ayers Badan: There’s No Phoning It In
In this episode of WORK, Erika talks about what it really means to show up prepared—at work, in your routines, and in your life. She…
Thought Leader: Erika Ayers Badan
Five Healthcare Priorities for the Class of 2023
Thought Leader: Anand Shah
Congress should give superbugs the PEPFAR treatment
Thought Leader: Anand Shah
